Blood Cancer United receives $4M from Mangurian Foundation for clinical trials and pediatric research

Blood Cancer United  has announced a $4 million commitment from the Harry T. Mangurian, Jr. Foundation to accelerate pediatric blood cancer research and treatment innovation. The funding will support AI-powered clinical trials and early-career scientists and emerging therapies research. The commitment boosts the foundation’s support for BCU to more than $25 million over the past 15 years, reinforcing a longstanding partnership that has advanced field-critical initiatives and expanded the pipeline for promising blood cancer treatments.